Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfenex, a protein production company, and Boehringer Ingelheim International have entered into a strategic agreement, under which Boehringer Ingelheim will get non-exclusive access to the Pfenex Expression Technology.
Subscribe to our email newsletter
Pfenex Expression Technology platform is based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals.
Under the multi-year agreement, Pfenex will engineer production strains and processes for Boehringer Ingelheim‘s proprietary molecules, and molecules from the latter’s contract manufacturing customers.
The collaboration gives Boehringer Ingelheim and its customers access to an expression platform to enable quicker preclinical and clinical development.
Pfenex CEO Bertrand Liang said the partnership combines a cutting edge expression technology with the leading innovative pharmaceutical company and contract services provider.
Boehringer Ingelheim corporate SVP of Biopharmaceuticals Division Simon Sturge said the Pfenex Expression Technology delivers excellent expression rates, and they are looking forward to realizing customer projects with this technology.